Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A

NCT05500807 is registered in ClinicalTrials.gov with Bleeding and Clotting Disorders Institute Peoria, Illinois as lead sponsor.

NCT NCT05500807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05500807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A
Lead sponsor
Bleeding and Clotting Disorders Institute Peoria, Illinois
Phase
Phase 1
Overall status
Recruiting
Start date
November 1, 2022
Completion date
February 29, 2028
Enrollment
40 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

concomitant vwd and hemophilia, von willebrand disease, type 3